Correlation between immune-related adverse events and long-term outcomes in pembrolizumab-treated patients with unresectable hepatocellular carcinoma: A retrospective study

Figure 1 Flow diagram of the study. mTECIST: Modified response evaluation criteria in solid tumors criteria; CTCAE: Common Terminology Criteria for Adverse Events; HCC: Hepatocellular carcinoma; AFP: Alpha fetoprotein; DSA: Digital subtraction angiography; OS: Overall survival; TTP: Time to progression; BCLC: Barcelona Clinic Liver Cancer; PD-1: Programmed death 1; CT: Computed tomography; MRI: Magnetic resonance imaging; irAE: Immune-related adverse event.

Figure 2 Kaplan-Meier curves describing the overall survival of all patients (n = 190) and the time to progression of patients who achieved disease control (n = 99). A: Survival curve; B: Time to progression curve. OS: Overall survival; TTP: Time to progression.

Figure 3 Waterfall plots of percentage change in tumor burden from baseline (n = 190). The “y” axis represents the percentage change in tumor burden from baseline by treatment. The immune-related adverse events are distinguished by different colors. Negative/positive values represent maximum tumor reduction or minimum tumor increase, respectively. A: 91 patients had progressive disease; B: 99 patients achieved complete response, partial response, or stable disease. irAE: Immune-related adverse event.

Figure 4 Spider plot displaying tumor response in 25 patients with hypothyroidism. PD: Progressive disease; SD: Stable disease; PR: Partial response; TBS: Tumor burden score.

Figure 5 Prognosis comparison between hypothyroidism group and non-hypothyroidism group. A: Survival curve; B: Time to progression curve.